A Phase 4, multicentre, randomized, single-blind clinical trial to evaluate the immunogenicity of the live, attenuated, oral rotavirus vaccine (116E), ROTAVAC®, administered simultaneously with or without the buffering agent in healthy infants in India

A Phase 4, multicentre, randomized, single-blind clinical trial to evaluate the immunogenicity of the live, attenuated, oral rotavirus vaccine (116E), ROTAVAC®, administered simultaneously with or without the buffering agent in healthy infants in India

Background: The World Health Organization recommends that rotavirus vaccines should be included in all national immunization programs. Some currently licensed oral rotavirus vaccines contain a buffering agent (either as part of a ready-to-use liquid formulation or added during reconstitution) to red...

Full description

Bibliographic Details
Main Authors: Raches Ella, Radhika Bobba, Sanjay Muralidhar, Sudhir Babji, Krishna Mohan Vadrevu, Maharaj Kishan Bhan
Format: Article
Language:English
Published: Taylor & Francis Group 2018-07-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
rotavac®
buffer
immunogenicity
oral vaccine
rotavirus vaccine
Online Access:http://dx.doi.org/10.1080/21645515.2018.1450709

Internet

http://dx.doi.org/10.1080/21645515.2018.1450709

Similar Items